Cellebrite DI [CLBT] vs Microsoft [MSFT] Detailed Stock Comparison
Cellebrite DI
NASDAQ
Loading...
Microsoft
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Cellebrite DI wins in 5 metrics, Microsoft wins in 14 metrics, with 0 ties. Microsoft appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Cellebrite DI | Microsoft | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 69.09 | 39.67 | Microsoft |
| Price-to-Book Ratio | 11.14 | 11.86 | Cellebrite DI |
| Debt-to-Equity Ratio | 5.47 | 32.63 | Cellebrite DI |
| PEG Ratio | 46.55 | 34.36 | Microsoft |
| EV/EBITDA | 55.04 | 25.77 | Microsoft |
| Profit Margin (TTM) | -34.56% | 35.79% | Microsoft |
| Operating Margin (TTM) | 14.58% | 45.67% | Microsoft |
| EBITDA Margin (TTM) | 14.58% | 45.67% | Microsoft |
| Return on Equity | -81.98% | 33.61% | Microsoft |
| Return on Assets (TTM) | 5.95% | 14.58% | Microsoft |
| Free Cash Flow (TTM) | $121.56M | $74.07B | Microsoft |
| Dividend Yield | N/A | 0.83% | N/A |
| 1-Year Return | 2.38% | 25.86% | Microsoft |
| Price-to-Sales Ratio (TTM) | 10.42 | 14.14 | Cellebrite DI |
| Enterprise Value | $4.10B | $3,843.57B | Microsoft |
| EV/Revenue Ratio | 9.39 | 14.24 | Cellebrite DI |
| Gross Profit Margin (TTM) | 84.39% | 68.72% | Cellebrite DI |
| Revenue per Share (TTM) | $2 | $36 | Microsoft |
| Earnings per Share (Diluted) | $-0.72 | $12.95 | Microsoft |
| Beta (Stock Volatility) | 1.30 | 1.03 | Microsoft |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Cellebrite DI vs Microsoft Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Cellebrite DI | -1.62% | -0.22% | 8.19% | 21.25% | 3.07% | -14.64% |
| Microsoft | -0.87% | 1.16% | 5.17% | 5.28% | 46.42% | 25.18% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Cellebrite DI | 2.38% | 333.02% | 91.41% | 91.41% | 91.41% | 91.41% |
| Microsoft | 25.86% | 129.25% | 138.54% | 1,002.88% | 1,951.61% | 2,023.96% |
News Based Sentiment: Cellebrite DI vs Microsoft
Cellebrite DI
News based Sentiment: MIXED
The month of October 2025 presented a mixed picture for Cellebrite, with positive analyst upgrades and a 'Conviction List' inclusion offset by some institutional selling and tempered price target revisions. The upcoming Q1 2024 earnings release on May 9, 2024, will be a key catalyst for investors to assess the company's performance and future prospects, particularly in light of its focus on AI and potential benefits from federal spending.
Microsoft
News based Sentiment: POSITIVE
October was a strong month for Microsoft, marked by a massive AI infrastructure deal, robust earnings, and continued expansion in cloud computing. While the Xbox price increase presents a minor headwind, the overall narrative is overwhelmingly positive, indicating continued growth and strategic positioning for the future.
Performance & Financial Health Analysis: Cellebrite DI vs Microsoft
| Metric | CLBT | MSFT |
|---|---|---|
| Market Information | ||
| Market Cap | $4.67B | $3.82T |
| Market Cap Category | Mid cap | Mega cap |
| 10 Day Avg. Volume | 1,491,440 | 16,039,860 |
| 90 Day Avg. Volume | 1,759,980 | 18,638,250 |
| Last Close | $18.49 | $523.98 |
| 52 Week Range | $13.10 - $26.30 | $344.79 - $555.45 |
| % from 52W High | -29.70% | -5.67% |
| All-Time High | $26.30 (Feb 03, 2025) | $555.45 (Jul 31, 2025) |
| % from All-Time High | -29.70% | -5.67% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.18% | 0.13% |
| Quarterly Earnings Growth | 0.18% | 0.18% |
| Financial Health | ||
| Profit Margin (TTM) | -0.35% | 0.36% |
| Operating Margin (TTM) | 0.15% | 0.46% |
| Return on Equity (TTM) | -0.82% | 0.34% |
| Debt to Equity (MRQ) | 5.47 | 32.63 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $1.67 | $43.30 |
| Cash per Share (MRQ) | $1.93 | $10.71 |
| Operating Cash Flow (TTM) | $161.08M | $130.71B |
| Levered Free Cash Flow (TTM) | $122.92M | $54.82B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.83% |
| Last 12-Month Dividend | N/A | $4.23 |
Valuation & Enterprise Metrics Analysis: Cellebrite DI vs Microsoft
| Metric | CLBT | MSFT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 69.09 | 39.67 |
| Forward P/E | 46.55 | 34.36 |
| PEG Ratio | 46.55 | 34.36 |
| Price to Sales (TTM) | 10.42 | 14.14 |
| Price to Book (MRQ) | 11.14 | 11.86 |
| Market Capitalization | ||
| Market Capitalization | $4.67B | $3.82T |
| Enterprise Value | $4.10B | $3.84T |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 9.39 | 14.24 |
| Enterprise to EBITDA | 55.04 | 25.77 |
| Risk & Other Metrics | ||
| Beta | 1.30 | 1.03 |
| Book Value per Share (MRQ) | $1.67 | $43.30 |
Financial Statements Comparison: Cellebrite DI vs Microsoft
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | CLBT | MSFT |
|---|---|---|
| Revenue/Sales | $113.28M | $70.07B |
| Cost of Goods Sold | $17.68M | $21.92B |
| Gross Profit | $95.60M | $48.15B |
| Research & Development | $28.61M | $8.20B |
| Operating Income (EBIT) | $14.42M | $32.00B |
| EBITDA | $17.01M | $40.32B |
| Pre-Tax Income | $20.79M | $31.38B |
| Income Tax | $1.32M | $5.55B |
| Net Income (Profit) | $19.48M | $25.82B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | CLBT | MSFT |
|---|---|---|
| Cash & Equivalents | $90.48M | $28.83B |
| Total Current Assets | $523.48M | $156.64B |
| Total Current Liabilities | $287.80M | $114.21B |
| Long-Term Debt | $6.39M | $57.57B |
| Total Shareholders Equity | $363.49M | $321.89B |
| Retained Earnings | $-147.46M | $219.76B |
| Property, Plant & Equipment | $28.03M | $295.49B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | CLBT | MSFT |
|---|---|---|
| Operating Cash Flow | $28.07M | $36.04B |
| Capital Expenditures | $-2.34M | $-16.75B |
| Free Cash Flow | $18.54M | $20.30B |
| Debt Repayment | N/A | $-2.25B |
| Common Stock Repurchase | N/A | $-4.78B |
Short Interest & Institutional Ownership Analysis
| Metric | CLBT | MSFT |
|---|---|---|
| Shares Short | 8.02M | 53.79M |
| Short Ratio | 3.58 | 2.76 |
| Short % of Float | 0.07% | 0.01% |
| Average Daily Volume (10 Day) | 1,491,440 | 16,039,860 |
| Average Daily Volume (90 Day) | 1,759,980 | 18,638,250 |
| Shares Outstanding | 234.52M | 7.43B |
| Float Shares | 112.43M | 7.42B |
| % Held by Insiders | 0.43% | 0.00% |
| % Held by Institutions | 0.50% | 0.75% |
Dividend Analysis & Yield Comparison: Cellebrite DI vs Microsoft
| Metric | CLBT | MSFT |
|---|---|---|
| Last 12-Month Dividend | N/A | $4.23 |
| Last 12-Month Dividend Yield | N/A | 0.83% |
| 3-Year Avg Annual Dividend | N/A | $3.32 |
| 3-Year Avg Dividend Yield | N/A | 0.20% |
| 3-Year Total Dividends | N/A | $9.95 |
| Ex-Dividend Date | N/A | Nov 20, 2025 |